Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns naming Matthew Lynch .
Filed returns
20
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2024 | JKS Communications | Health | manifesto and pfg asks (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs. (Legislation) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | Budget 2025 (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA General Election Manifesto asks - (i) Faster Access to new Medicines and (ii) Increased number of Clinical Trials. (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2024 | MSD | Health | Health Policy Development for New Programme for Government (Public policy or programme) | 46 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA General Election Manifesto asks (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2024 | BioMarin International Limited | Health | Rare disease policy in Ireland and EU (Legislation) | 20 | On lobbying.ie |
| May–Aug 2024 | Vulcan Consulting Limited | Health | Rare Disease Policy (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2024 | BioMarin International Limited | Health | Rare disease policy and access to treatments in Ireland and EU (Legislation) | 29 | On lobbying.ie |
| Jan–Apr 2024 | Shine | Health | Nicola Byrne (Shine's CEO) congratulated Taoiseach Simon Harris on his recent appointment and provided him with relevant information about Shine. (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2023 | BioMarin International Limited | Health | Rare disease policy in Ireland and the EU (Legislation) | 43 | On lobbying.ie |
| May–Aug 2023 | Novo Nordisk Limited | Health | To discuss the importance of an innovative life science ecosystem in Ireland, outlining Novo Nordisk position on the revision of the EU General Pharmaceutical Legislation. (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2023 | Gilead Sciences Ireland UC | Health | HIV, Hepatitis-C & Oncology healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2021 | Hume Brophy | Health | Furniture Fire Regulations (FFRs) (Legislation) | 7 | On lobbying.ie |
| Sep–Dec 2021 | Acquired Brain Injury Ireland | Health | Implementing the Neuro-rehabilitation Strategy/Implementation Framework (Public policy or programme) | 40 | On lobbying.ie |
| May–Aug 2021 | Roche Diagnostics Ltd | Health | Briefing document for Department of Enterprise Trade an Employment, trade mission to UK (September 6th) (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | BioMarin International Limited | Health | Rare disease policy in Ireland and EU (Public policy or programme) | 19 | On lobbying.ie |
| Jan–Apr 2020 | Hume Brophy | Health | Seeking clarification on the scope of any regulations made under the Health (Preservation and Protection and other Emergency Measures in the Public Interest) Bill 2020 for preventing, limiting, minimising or slowing… (Legislation) | 11 | On lobbying.ie |
| Sep–Dec 2019 | Edelman Ireland | Health | Making representations in relation to a pre budget submission made by the VHG. Subsequently, in the context of the Health Service Plan, Making the case for an increase in funding for The Voluntary Hospice Group to… (Matters involving public funds) | 4 | On lobbying.ie |
| May–Aug 2017 | Ibec | Health | Public Health (Alcohol) Bill 2015 (Legislation) | 3 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 20 | 100.0% |